Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study

Overview of attention for article published in Blood, December 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 33 news outlets
blogs: 3 blogs
policy: 2 policy sources

twitter: 26 X users
patent: 2 patents
wikipedia: 1 Wikipedia page

Citations

dimensions_citation: 240 Dimensions

Readers on

mendeley: 241 Mendeley

Summary News Blogs Policy documents X Patents Wikipedia Dimensions citations

So far, Altmetric has seen 3 policy documents that reference this research output.

ravulizumab

Cited by Canadian Agency for Drugs and Technologies in Health on 22 Apr 2022

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

Ravulizumab for treating atypical haemolytic uraemic syndrome : Committee papers

Cited by National Institute for Health and Care Excellence on 04 Jun 2021

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Ravulizumab for treating paroxysmal nocturnal haemoglobinuria : Committee papers

Cited by National Institute for Health and Care Excellence on 08 Apr 2021

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.